An observational study in Acute Intermittent Porphyria, Hereditary Coproporphyria and Variegate Porphyria, sponsored by The University of Texas Medical Branch, Galveston. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-12.
Sponsored by The University of Texas Medical Branch, Galveston · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Porphyria, Acute Intermittent with a site in United States — 2 open to participants now, 3 under way, none of them phase 3. Porphyria, Acute Intermittent · United States.
Among the 12 studies in Porphyria, Acute Intermittent with a site in United States, this one is one of 2 that started in 2014, is one of 6 observational ones, and was the 7th registered.
21 studies on the registry are indexed under Porphyria, Acute Intermittent; 3 are open to participants now.
Browse Porphyria, Acute Intermittent studies →2 of the 12 studies in Porphyria, Acute Intermittent with a site in United States are open now. Recruiting first, the newest first:
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 12+
The American Porphyrias Expert Collaborative · Sites in United States
Ages 1 min+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 3 Porphyria, Acute Intermittent studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 2 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 2
First in 2003; this study’s year is marked. 2 started in 2014.
Median enrollment 28 across the 6 interventional studies, 149 across the 6 observational. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 12 have an industry lead sponsor. The 7 most frequent:
The University of Texas Medical Branch, Galveston is the lead sponsor of 257 studies on the registry; 36 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 26 (81%) have results posted.
The University of Texas Medical Branch, Galveston has 3 studies filed under Porphyria, Acute Intermittent — fewer than ten, so there is no comparison to draw.
1 of the studies in Porphyria, Acute Intermittent with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02935400The University of Texas Medical Branch, GalvestonAcute Porphyria Biomarkers for Disease Activity | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Porphyria, Acute Intermittent with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The long term objective of the research is to identify new biomarkers of disease activity in the human acute porphyrias. This pilot study is intended to provide pilot and feasibility data needed to plan larger and more definitive future studies.
This translational pilot research is based on preliminary results using animal models. The investigators will collect samples of blood, urine and feces from up to 50 participants with well documented acute porphyrias, at 2 expert sites that are members of the Porphyrias Consortium. Collection and analysis of these samples will be used to assess feasibility of performing such studies in humans with acute porphyrias, recognizing that these disorders are more heterogeneous than reproduced in animal models, and affect individuals who cannot all be studied simultaneously and in large groups. Therefore, we will assess the feasibility of methods for collecting, processing, storing and shipping samples at multiple study sites for later biomarker analysis. Larger and more definitive studies of biomarkers will be designed and implemented based on data and experience from this pilot-feasibility study.
Acute intermittent porphyria, hereditary coproporphyria, variegate porphyria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Documented diagnosis of acute porphyria.
Exclusion Criteria:
Group 1 will have had no symptoms of porphyria in the past year.
Group 2 will have a history of symptoms within the past year.
Drug: Hemin
Hemin will be administered under a separate protocol or for clinical treatment, and samples will be collected under this protocol before and after treatment.
Also known as: Panhematin
Potential biomarkers Biomarkers
Expression of heme biosynthetic and heat and stress response genes
Time frame: 10 days
Plan to share: Undecided — Data not entered
No publications or documents are linked to this record.
Started Apr 2014 (actual). Primary completion is estimated for Dec 2026, 152 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Porphyria, Acute Intermittent →
The University of Texas Medical Branch, Galveston →